Spots Global Cancer Trial Database for Window of Opportunity Study of Preoperative Immunotherapy With Atezolizumab in Local SCCHN

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Window of Opportunity Study of Preoperative Immunotherapy With Atezolizumab in Local SCCHN

Official Title: Window of Opportunity Study of Preoperative Immunotherapy With Atezolizumab (Tecentriq®) in Local Head and Neck Squamous Cell Carcinoma (the PIONEER Trial)

Study ID: NCT04939480

Conditions

Squamous Cell Carcinoma of Head and Neck

Interventions

Atezolizumab

Study Description

Brief Summary: Targeting the PD-L1 pathway with atezolizumab has demonstrated objective responses across a broad range of malignancies including head and neck squamous cell carcinoma (SCCHN). MO39839 is a window of opportunity study investigating the feasibility, safety and postoperative complication rates of preoperative short time immunotherapy with atezolizumab in patients with local SCCHN. In the scope of MO39839 a comprehensive translational research program will be conducted to assess the potential effect of atezolizumab on dynamics in tumor immunity, and to identify and validate potential predictive and prognostic biomarkers.

Detailed Description: